Oct 30 (Reuters) – AstraZeneca on Friday announced a restructuring programme aimed at supporting pipeline investments with benefits of about $1.5 billion to keep the drugmaker on track to achieve its target of generating $80 billion in annual revenue by 2030.
The moves were announced alongside third-quarter results, which surpassed analyst expectations.
(Reporting by Pushkala Aripaka, Sri Hari N S in Bengaluru and Patrick Wingrove in London; Editing by Janane Venkatraman)
Comments